本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，珠海润都制药股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价 值领航--投资者集体接待日暨辖区上市公司中报业绩说明会"活动，现将相关事 项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 09 月 19 日（周 五）15:30-17:00。 证券代码：002923 证券简称：润都股份 公告编号：2025-042 珠海润都制药股份有限公司 关于参加 2025 年广东辖区上市公司 投资者集体接待日暨中报业绩说明会活动的公告 董事会 2025 年 09 月 17 日 届时公司董事长陈新民先生，董事、总经理刘杰先生，独立董事叶建木先生， 副总经理、财务负责人石深华先生，董事会秘书苏军先生将在线就 2025 年半年 度业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公 ...

证券日报网讯润都股份（002923）9月11日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东总户数为24，743户。 ...

证券代码：002923 证券简称：润都股份 珠海润都制药股份有限公司 3、看到公司《烟草专卖生产企业许可证》今年续证成功，那公司下 一步尼古丁相关产品的战略布局是什么样的？ 答：2025 年 7 月，公司通过了国家烟草专卖局的严格核查，顺利将《烟 草专卖生产企业许可证》的有效期延长至 2028 年 6 月 30 日。公司将持续 关注尼古丁相关产品的发展趋势及国家法规政策，依托尼古丁原料生产企 业的优势，根据市场动态及政策法规的变化进行灵活调整。 4、请问公司研发的 1 类新药盐酸去甲乌药碱注射液最新的审批进展？ 答：公司 1 类创新药盐酸去甲乌药碱注射液已于 2024 年 3 月向国家 药品监督管理局提交注册申请，并获得受理，同年 12 月，公司收到药学 补充资料通知，于 2025 年 4 月完成补充研究并提交相关资料（此次发补， 无临床相关内容）。截至目前，相关程序已进入 CDE 排队审评序列。 5、请介绍一下公司上半年原料药、制剂净利下降的原因。 投资者关系活动记录表 编号：2025-006 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明 ...

（编辑 袁冠琳） 证券日报网讯 润都股份9月8日在互动平台回答投资者提问时表示，公司的1类创新药盐酸去甲乌药碱注 射液已于2024年3月向国家药品监督管理局提交注册申请，并获得受理，同年12月，公司收到药学补充 资料通知，于2025年4月完成补充研究并提交相关资料（此次发补，无临床相关内容）。截至目前，相 关程序已进入后续审评序列。后续如有重大进展，公司将会严格按照信息披露规定，及时履行信息披露 义务。公司全资子公司——润都制药（荆门）有限公司生产的尼古丁品质获得客户广泛认可，可用于相 关新型烟草产品生产，上半年销量显著提升，目前这一业务尚未对公司整体经营业绩产生重大影响。公 司将持续关注新型烟草终端产品的发展趋势，积极寻求合作与发展机会。 ...

| 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 芬太尼 | 0.65 | 兵装重组概念 | -7.44 | | BC电池 | 0.39 | 国产航母 | -5.45 | | 青蒿素 | 0.17 | 军工信息化 | -4.97 | | 光刻胶 | 0.10 | 成飞概念 | -4.76 | | 重组蛋白 | 0.03 | 军民融合 | -4.67 | | 石墨电极 | 0.02 | 大飞机 | -4.10 | | HJT电池 | -0.23 | 中船系 | -4.07 | | 光刻机 | -0.25 | 航空发动机 | -3.87 | | 减肥药 | -0.27 | 商业航天 | -3.71 | | 创新药 | -0.43 | 卫星导航 | -3.59 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.58亿元，其中，3股获主力资金净流入，净流入 资金居首的是百花医药，今日主力资金净流入1.09亿元，净流入资金居前的还有华润双鹤、浙江医药 等，主力资金分别净流入1416.28万元、579.44万元。 （原标题：青蒿素概念涨0.17 ...

Summary of Key Points Core Viewpoint - The company, Rundu Co., has experienced a significant decline in shareholder numbers and financial performance, indicating potential challenges ahead [2]. Shareholder Information - As of August 31, the number of shareholders for Rundu Co. was 25,794, a decrease of 3,564 from the previous period (August 20), representing a 12.14% decline [2]. - This marks the second consecutive period of decline in shareholder numbers [2]. Stock Performance - The closing price of Rundu Co. was 13.88 yuan, down 0.86%, with a cumulative decline of 6.28% since the concentration of shares began [2]. - The stock experienced 2 days of increase and 8 days of decrease during the reporting period [2]. Financial Performance - For the first half of the year, Rundu Co. reported total revenue of 548 million yuan, a year-on-year decrease of 8.22% [2]. - The net profit for the same period was -36.19 million yuan, reflecting a year-on-year decline of 195.75% [2]. - The basic earnings per share were reported at -0.1100 yuan [2].

Core Viewpoint - Recent financial report from Rundu Co., Ltd. shows significant declines in key financial metrics, indicating potential challenges in operational performance and profitability [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 548 million yuan, a decrease of 8.22% compared to 597 million yuan in 2024 [1]. - Net profit attributable to shareholders was -36.19 million yuan, reflecting a drastic decline of 195.75% from a profit of 37.80 million yuan in the previous year [1]. - Gross margin decreased to 36.41%, down 25.16% year-on-year, while net margin turned negative at -6.6%, a drop of 204.32% [1]. - Total expenses (selling, administrative, and financial) reached 174 million yuan, accounting for 31.73% of revenue, an increase of 8.51% year-on-year [1]. - Earnings per share fell to -0.11 yuan, a decrease of 200% from 0.11 yuan in the previous year [1]. Cash Flow and Debt Analysis - Operating cash flow per share decreased by 88.54% to 0.03 yuan, indicating reduced cash generation from operations [1][3]. - The company’s cash and cash equivalents increased by 58.84% to 202 million yuan, while interest-bearing liabilities rose by 17.55% to 607 million yuan [1][3]. - The cash flow from investing activities improved by 85.24%, attributed to reduced long-term asset investments [3]. Business Model and Market Position - The company’s return on invested capital (ROIC) was reported at 3.2%, significantly lower than the historical median of 16.01%, indicating weak capital returns [3]. - The business model relies heavily on research and marketing, necessitating a thorough examination of the underlying drivers of performance [3]. - The company is focusing on expanding its product matrix in various therapeutic areas, including cardiovascular, digestive, and pain relief medications [5][6]. Product Development and Market Trends - The company is developing a new chemical drug, the hydrochloride of deoxynoradrenaline, which is positioned for use in cardiac stress testing [5]. - Sales of nicotine products have shown significant growth, although they have not yet had a major impact on overall performance [5]. - The company aims to enhance its generics and innovative drug development, particularly in high-tech barrier generics and original new drugs [6].

2023 2024 2025 ■ 营业总收入-中报(亿) ■ 单季度营业总收入-第二季度(亿) 一 归母净利润 - 归母净利润-中报(万) -3619.31 同比 -195.74% 单季度归母净利润-第二季度(万) -3806.13 同比 -535.20% 6925.19 3780.14 2881.97 874.56 -3619.33 3806.12 2023 2024 ■ 归母净利润-中报(万) ■ 单季度归母净利润-第二季度(万) 一 扣非净利润 一 扣非净利润-中报(万) -4484.80 同比 -242.47% 单季度扣非净利润-第二季度(万) -4258.53 同比 -821.03% 5602.88 3147.86 1960.23 590.61 -4484.79-4258.52 2023 2025 2024 ■ 扣非净利润-中报(万) ■ 单季度扣非净利润-第二季度(万) l 财务数据 销售毛利率 (%) 36.41 同比 -25.16% 证券之星消息，润都股份2025年中报显示，公司主营收入5.48亿元，同比下降8.22%；归母净利 润-3619.31万元，同比下降195.75%；扣非净利润-44 ...

Core Viewpoint - Zhuhai Rundu Pharmaceutical Co., Ltd. reported a significant decline in financial performance for the first half of 2025, with a notable drop in revenue and net profit compared to the same period last year [3][4]. Financial Performance - The company's revenue for the first half of 2025 was approximately 548.07 million yuan, a decrease of 8.22% from 597.17 million yuan in the same period last year [3]. - The net profit attributable to shareholders was a loss of approximately 36.19 million yuan, a decline of 195.75% compared to a profit of 37.80 million yuan in the previous year [3]. - The net cash flow from operating activities was approximately 9.45 million yuan, down 88.54% from 82.46 million yuan in the previous year [3]. - Basic and diluted earnings per share were both -0.11 yuan, compared to 0.11 yuan in the previous year, indicating a 200% decline [3]. Industry Overview - The pharmaceutical industry in China is undergoing a transformation, with a focus on high-quality development and innovation, supported by new regulatory frameworks [4][5]. - The industry saw a revenue of 1,227.52 billion yuan, a slight decrease of 1.2% year-on-year, indicating a challenging market environment [6]. Business Operations - The company specializes in the research, production, and sales of chemical drug formulations and raw materials, focusing on therapeutic areas such as cardiovascular, anti-infection, digestive, analgesic, and anesthetic treatments [4][6]. - The company has established a complete industrial chain from intermediates to raw materials and formulations, enhancing its competitive edge in the market [6][8]. Product Development - The company has submitted three product registration applications during the reporting period, indicating ongoing efforts to expand its product portfolio [8]. - The company’s raw materials and intermediates have been recognized for their quality, with products sold in major markets including Europe, the USA, Japan, and South Korea [7][10]. Market Strategy - The company is actively developing new markets, particularly in North Africa and the Middle East, while enhancing its service quality and brand recognition [11][12]. - The marketing strategy focuses on a customer-centric approach, combining direct and distributor sales to improve market penetration [7][11].

Core Viewpoint - Zhuhai Rundu Pharmaceutical Co., Ltd. reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance and financial health [2][3]. Financial Performance - The company's operating revenue for the reporting period was approximately 548.07 million yuan, a decrease of 8.22% compared to the same period last year [2]. - The net profit attributable to shareholders was a loss of approximately 36.19 million yuan, representing a decline of 195.75% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was a loss of approximately 44.85 million yuan, down 242.47% from the previous year [2]. - The net cash flow from operating activities was approximately 9.45 million yuan, a decrease of 88.54% compared to the same period last year [2]. - Basic and diluted earnings per share were both -0.11 yuan, a drop of 200% year-on-year [2]. - The weighted average return on equity was -3.22%, down 6.40% from the previous year [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately 2.12 billion yuan, a decrease of 3.35% from the end of the previous year [3]. - The net assets attributable to shareholders were approximately 1.07 billion yuan, down 7.50% from the previous year-end [3]. Shareholder Information - The top two shareholders, Li Xi and Chen Xinmin, each hold 30.12% of the shares, collectively controlling 60.24% of the company [3][4]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4]. Important Events - The company clarified that it has not engaged in the production or sale of toxic or harmful food products, despite allegations against another pharmaceutical company [4]. - The company is actively monitoring the situation and will fulfill its disclosure obligations as required by law and the Shenzhen Stock Exchange [4].